1. Peptides

ARA290 (Synonyms: Cibinetide)

Cat. No.: HY-P0168 Purity: 98.97%
Handling Instructions

ARA290 is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

For research use only. We do not sell to patients.
ARA290 Chemical Structure

ARA290 Chemical Structure

CAS No. : 1208243-50-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 2489 In-stock
1 mg USD 312 In-stock
5 mg USD 1032 In-stock
10 mg USD 1800 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


ARA290 is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

In Vitro

ARA290 enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. ARA290 is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2].

In Vivo

After ECFC transplantation to mice with CLI, a single ARA290 injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation[1]. ARA290 (30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. ARA290 significantly decreases glucose AUCs in IPGTT in GK rats[2]. Low-dosage ARA290 (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. ARA290-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way[3].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 0.7953 mL 3.9767 mL 7.9535 mL
5 mM 0.1591 mL 0.7953 mL 1.5907 mL
10 mM 0.0795 mL 0.3977 mL 0.7953 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Diabetic Goto-Kakizaki (GK) rats, originating from Wistar rats, are bred in our department. Normal Wistar (W) rats are used as nondiabetic controls. All animals are about six weeks old and with body weights 100 to 150 g when treatment is initiated. They are kept at 22°C on a reversed 12-h light-dark cycle with free access to food, except when fasted overnight as noted below. Rats are treated over 4 wks with ARA290 by a once daily subcutaneous (s.c.) injection at a dose of 30 μg/kg body weight or PBS. Blood samples for determination of glucose are taken after a small tail incision and analyzed every week before morning s.c. injection of either ARA290 or placebo. During the experimental period, body weights are measured weekly. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight








Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 34 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: